In Section C, members will get ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment till sickness progression or the participants are unable to tolerate the study drugs. Ubiquitin-related proteins that control The soundness of vital Tremendous enhancer-mediated proteins have also been https://abbv-744-therapeutic-pote46891.blogoscience.com/38100364/top-brd4-inhibition-by-abbv-744-in-cancer-research-studies-secrets